The patient arrives in the emergency department breathing three to four times faster than normal — a physiologic response to the lungs’ inability to transmit sufficient oxygen to the body. It creates a sensation one might feel if they were drowning. She looks scared. Desperate. I introduce myself as an emergency medicine physician and try to reassure her that she’ll feel more comfortable with the supplemental oxygen the nurse is busily setting up.
The patient has already been diagnosed with COVID-19 and had been attempting to recover at home before her symptoms worsened, prompting her to return to the hospital. She manages a question through her gasps for air: “Is there a medicine for this yet?”
Like most of my colleagues, I’ve spent countless hours following the COVID-19 medical literature in anticipation of a treatment for patients like the one I described. Unfortunately, the reality is that there are no proven therapies, and despite considerable excitement and fanfare, much of the research thus far has been lackluster and driven by pharmaceutical companies motivated by financial interests.
Many of the interventions proposed thus far involve adapting existing medicines like the malarial drug chloroquine or the antifungal ivermectin, in hopes that the drugs might be useful treating the novel coronavirus. Unfortunately, the results have been disappointing. The biological implausibility of using medications that were developed to treat nonviral illnesses has led many clinicians and scientists to view these interventions skeptically. However, it has not stopped officials pushing them as treatment options.
Remdesivir, an antiviral originally developed to treat hemorrhagic fever caused by Ebola and Marburg viruses, is the latest potential treatment to drum up considerable excitement.
The initial study used as justification for its use consisted of a small collection of COVID-19 patients. While a large proportion of the patients taking the drug improved, there was no control group for comparison, making it impossible to credit remdesivir for their improvement. This is a far cry from the accepted standard for testing a new therapy — a randomized control trial, where a treatment group receives the new drug and their clinical outcome is compared to a control group that received standard measures or a placebo. That didn’t stop Gilead, the pharmaceutical company that owns remdesivir, from boasting success, raising hope — and their own stock prices.
The decision to conduct a methodologically dubious study such as the one described — and its subsequent publication in one of the world’s top medical journals — at best reflects the medical field’s desperation during a crisis, in which there is a willingness to sacrifice quality data for speedy results. A less generous view would see this as a cynical ploy to stir up excitement for a drug without the risk of a negative trial — where the treatment group shows no significant improvement compared to a control group.
One might point out the difficulty in running a well-designed clinical trial, with both treatment and control groups, under the burden of a global pandemic — where much of our overtaxed health care resources are focused on the delivery of care, making large multi-institutional clinical trials a distant second priority. In that respect, remdesivir’s use in other settings provides an instructive lesson.
Last December, a team of researchers published the results of a randomized controlled trial (where participants are randomly assigned to either experimental treatment or standard care) comparing remdesivir to other treatments for Ebola virus disease. What’s remarkable about the study is not that the researchers were able to employ such rigorous research methodology, it’s that they did it in the war-torn Congo … during an Ebola virus outbreak.
For their part, Gilead has initiated multiple clinical trials to further evaluate the remdesivir’s effectiveness in treating COVID-19. Last month, preliminary data was released from a National Institute of Allergy and Infectious Diseases study showing modest benefit to infected patients receiving the drug in terms of length of hospital stay, though it failed to show a decrease in mortality. The medical journal The Lancet, perhaps in an effort to tamp overzealous excitement, released data from a yet-to-be published randomized controlled trial that refutes this modest benefit and suggests remdesivir may not be useful in COVID-19 patients. Despite limitations of preliminary data, the U.S. Food and Drug Administration announced that it would authorize the regular use of the drug in hospitalized patients, stoking the frenzied buzz that a treatment might be within reach.
Incidentally, the recent trial of remdesivir for Ebola in the Congo refuted earlier, methodologically inferior studies, and suggested that other treatments were in fact superior to remdesivir for use in Ebola virus disease. This is not to say that the drug’s effectiveness, or lack thereof, in treating Ebola can be used as evidence for how it may fare with regards to COVID-19 — a completely different disease process. However, the story of a novel treatment which showed promise in early studies, only to prove disappointing in later, more rigorous ones is worth keeping in mind as the science unfolds for remdesivir’s use in COVID-19.
Like all physicians, I yearn to tell patients like the one I described that, indeed I do have a medicine to give you. But I want to know that its indication is based on medical science and not corporate greed or panicked imprudence. The researchers studying Ebola in the Congo prove that a calamity is no excuse for sloppy science. In fact, in times of crisis such as these, society relies on medical science to be a bulwark of rationality.
We’re not backing down in the face of Trump’s threats.
As Donald Trump is inaugurated a second time, independent media organizations are faced with urgent mandates: Tell the truth more loudly than ever before. Do that work even as our standard modes of distribution (such as social media platforms) are being manipulated and curtailed by forces of fascist repression and ruthless capitalism. Do that work even as journalism and journalists face targeted attacks, including from the government itself. And do that work in community, never forgetting that we’re not shouting into a faceless void – we’re reaching out to real people amid a life-threatening political climate.
Our task is formidable, and it requires us to ground ourselves in our principles, remind ourselves of our utility, dig in and commit.
As a dizzying number of corporate news organizations – either through need or greed – rush to implement new ways to further monetize their content, and others acquiesce to Trump’s wishes, now is a time for movement media-makers to double down on community-first models.
At Truthout, we are reaffirming our commitments on this front: We won’t run ads or have a paywall because we believe that everyone should have access to information, and that access should exist without barriers and free of distractions from craven corporate interests. We recognize the implications for democracy when information-seekers click a link only to find the article trapped behind a paywall or buried on a page with dozens of invasive ads. The laws of capitalism dictate an unending increase in monetization, and much of the media simply follows those laws. Truthout and many of our peers are dedicating ourselves to following other paths – a commitment which feels vital in a moment when corporations are evermore overtly embedded in government.
Over 80 percent of Truthout‘s funding comes from small individual donations from our community of readers, and the remaining 20 percent comes from a handful of social justice-oriented foundations. Over a third of our total budget is supported by recurring monthly donors, many of whom give because they want to help us keep Truthout barrier-free for everyone.
You can help by giving today. Whether you can make a small monthly donation or a larger gift, Truthout only works with your support.